Results 21 to 30 of about 8,561 (174)

Zonisamide Increases Dopamine Turnover in the Striatum of Mice and Common Marmosets Treated With MPTP

Journal of Pharmacological Sciences, 2009
.: The effect of zonisamide, an antiepileptic agent with anti-parkinsonian effects, was studied on dopamine neurons of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 mice and common marmosets. Groups of mice (n = 8 – 9) were treated with:
Hayato Yabe, Mohammed Emamussalehin Choudhury, Madoka Kubo, Noriko Nishikawa, Masahiro Nagai, Masahiro Nomoto   +5 more
doaj   +1 more source

Comparison of the Effects of Zonisamide and Flupirtine on Paclitaxel Induced Peripheral Neuropathy in Rats [PDF]

Journal of Clinical and Diagnostic Research, 2018
Introduction: Many peripheral and central causes lead to neuropathic pain disorders. Effective treatment of neuropathic pain is not completely manageable and hence, it becomes necessary to evaluate the application of Zonisamide as a sodium channel and T ...
Bhuvaneswari Krishnamurthy, Prashanth Ashok Kumar, Abilash Sathyanarayanan   +2 more
doaj   +1 more source

Zonisamide improves axial symptoms in dementia with Lewy bodies with parkinsonism: Post hoc analysis of clinical trials

eNeurologicalSci, 2022
Patients with dementia with Lewy bodies (DLB) experience worsening axial symptoms with disease progression, which can negatively affect quality of life.
Yoshio Tsuboi, Kenji Kochi, Hidenori Maruyama, Yuji Matsumoto   +3 more
doaj   +1 more source

The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data

Drug Design, Development and Therapy, 2021
Babak Tousi,1,2 James B Leverenz2 1Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA; 2Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, OH, USACorrespondence: Babak TousiLou Ruvo Center for ...
Tousi B, Leverenz JB
doaj  

Quantification of Zonisamide in Dried Blood Spots and Dried Plasma Spots by UPLC–MS/MS: Application to Clinical Practice

Molecules, 2022
In this research, a UHPLC–MS/MS method was developed and validated for the determination of zonisamide in dried plasma spots (DPS) and dried blood spots (DBS).
Milena Rmandić, Ana Stajić, Jasna Jančić, Janko Samardžić, Nebojša Jović, Anđelija Malenović   +5 more
doaj   +1 more source

Review: A review of the use of zonisamide in Parkinson’s disease

Therapeutic Advances in Neurological Disorders, 2009
Although zonisamide was previously only used to treat epilepsy, recently more applications have been forthcoming. Due to a good side effect profile, a lower frequency of interactions and a more comfortable posology, there are several studies regarding ...
Pedro Emilio Bermejo, Buenaventura Anciones   +1 more
doaj   +1 more source

Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease

Cells, 2018
Although many experimental studies have shown the favorable effects of zonisamide on mitochondria using models of Parkinson’s disease (PD), the influence of zonisamide on metabolism in PD patients remains unclear.
Shin-Ichi Ueno, Shinji Saiki, Motoki Fujimaki, Haruka Takeshige-Amano, Taku Hatano, Genko Oyama, Kei-Ichi Ishikawa, Akihiro Yamaguchi, Shuko Nojiri, Wado Akamatsu, Nobutaka Hattori   +10 more
doaj   +1 more source

Zonisamide for the Treatment of Parkinson Disease: A Current Update

Frontiers in Neuroscience, 2020
Zonisamide has been used as an add-on treatment in order to overcome the deficiencies of the general therapies currently used to resolve the motor complications and non-motor symptoms of Parkinson disease. Various trials have been designed to investigate
Chengqian Li, Li Xue, Yumei Liu, Zhengjie Yang, Song Chi, Anmu Xie   +5 more
doaj   +1 more source

Refining Domain‐Based Prognostication in DNM1 Encephalopathy: A Mild Phenotype Associated With a GTPase Domain Variant

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT DNM1 encephalopathy is a rare autosomal dominant genetic condition characterized by a range of neurological and developmental manifestations. The typical phenotype is severe, including profound intellectual disability, treatment‐resistant epilepsy, ataxia, and structural brain abnormalities. However, milder presentations have increasingly been
Caroline Crain, Hope Northrup, Laura S. Farach, Sureni V. Mullegama, Kathleen Shields, Gretchen Von Allmen, Kate Richardson   +6 more
wiley   +1 more source

Neuroinflammation following anti-parkinsonian drugs in early Parkinson’s disease: a longitudinal PET study

Scientific Reports
The progression of neuroinflammation after anti-parkinsonian therapy on the Parkinson’s disease (PD) brain and in vivo evidence of the therapy purporting neuroprotection remain unclear.
Tatsuhiro Terada, Tomoyasu Bunai, Takanori Hashizume, Takashi Matsudaira, Masamichi Yokokura, Hirotsugu Takashima, Takashi Konishi, Tomokazu Obi, Yasuomi Ouchi   +8 more
doaj   +1 more source